secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003868
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Setrusumab OI trials on track; alvelestat FDA alignment; leflutrozole licensed for up to $64.25M
--------------------------------------------------------------------------------

- Setrusumab: Phase 3 Orbit study (195 patients) expected full enrollment around end Q1 2024; Cosmic study (~65 patients) expected full enrollment 1H 2024.
- Phase 2 data showed 67% reduction in annualized fracture rate; additional data expected 2024.
- Alvelestat: FDA aligned on Phase 3 design with SGRQ Total Score as primary endpoint; could support full U.S. approval.
- Leflutrozole: global license deal with ReproNovo; Mereo received upfront payment and up to $64.25M in milestones plus tiered royalties.
- Cash runway guidance reaffirmed: existing cash expected to fund operations into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524003868/0001193125-24-003868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524003868/d100759d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer